98.9%
epoetin betadenosumabsecukinumabrheumatoid arthritischronic kidney diseaseprostate cancerosteoporosispharmacotherapy
…h-cost biologics such as denosumab (12%), secukinumab (8%), and epoetin beta (6%).Conclusion and Relevance The hospital pharmacy-led CMM pro…